DEF: Nature's Sunshine Sets 2026 Annual Meeting Agenda

Nature's Sunshine Products, Inc. announces its 2026 Annual Meeting of Shareholders to address director elections, executive compensation, auditor ratification, and a new stock incentive plan.

Summary

• The 2026 Annual Meeting of Shareholders will be held on Wednesday, May 6, 2026, at 10:00 a.m. Mountain Daylight Time.
• The agenda includes the election of eight directors, an advisory vote on named executive officer compensation, ratification of Deloitte & Touche LLP as the independent auditor for 2026, and approval of the 2026 Stock Incentive Plan.
• The record date for voting at the Annual Meeting is February 27, 2026.
• Net sales increased by 2.7% to $480.1 million in 2025 compared to 2024, or 5.3% excluding the unfavorable impact of foreign currency exchange rate fluctuations.
• Net income for 2025 was $20.5 million, a significant increase from $7.9 million in 2024.
• Adjusted EBITDA for 2025 was $49.4 million, up from $40.5 million in 2024.
• Total Shareholder Return (TSR) for 2025 was $259.38, based on a $100 investment on December 31, 2022.
• The Board of Directors unanimously recommends a vote 'FOR' all proposals.
• The proposed 2026 Stock Incentive Plan seeks to reserve 1,500,000 shares of common stock for future awards, as the prior 2012 Stock Incentive Plan expired on March 3, 2026.
• Kenneth Romanzi was appointed Chief Executive Officer effective October 29, 2025, following the termination of former CEO Terrence Moorehead's employment on October 28, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong financial performance in 2025, including increased sales, net income, and Adjusted EBITDA, alongside robust corporate governance practices. However, the increase in fully-diluted overhang and the need for a new stock incentive plan after the previous one expired introduce some cautionary notes.

Positives

• Net sales increased by 2.7% in 2025 to $480.1 million, or 5.3% excluding unfavorable foreign currency impact, demonstrating operational growth.
• Adjusted EBITDA rose significantly to $49.4 million in 2025 from $40.5 million in 2024, indicating improved profitability.
• Net income more than doubled to $20.5 million in 2025 from $7.9 million in 2024.
• Total Shareholder Return (TSR) showed strong performance, reaching $259.38 based on a $100 investment on December 31, 2022, reflecting substantial shareholder value creation.
• The Board of Directors maintains a strong independent majority, with 7 of 8 directors being independent, ensuring robust oversight.
• The company has implemented comprehensive corporate governance guidelines, including age and term limits for directors, separate Chairman and CEO roles, and stock ownership guidelines for directors and executives.
• A Clawback Policy is in place for erroneously awarded incentive compensation, enhancing accountability.
• Executive officers and the Board are prohibited from hedging, pledging, or short selling company stock, aligning their interests with long-term shareholder value.
• The proposed 2026 Stock Incentive Plan is designed to attract and retain key personnel, which is vital for the company's long-term growth and success.

Negatives

• The prior 2012 Stock Incentive Plan expired on March 3, 2026, necessitating the approval of a new plan to continue offering equity incentives; failure to approve the 2026 Plan could negatively impact talent recruitment and retention.
• The company experienced a change in CEO in October 2025, with Terrence Moorehead's employment terminated and Kenneth Romanzi appointed, which could signal a period of transition or strategic shift.
• Certain Section 16(a) reports were filed late for Mr. Brower, Mr. Norman, Mr. Yates, and Mr. Fritz in 2025, indicating minor compliance issues.
• The fully-diluted overhang would increase from 7.7% to 14.5% if the 2026 Stock Incentive Plan is approved, suggesting potential dilution for existing shareholders.
• The gross usage (burn rate) of RSUs and Performance RSUs increased significantly to 4.8% in 2025, up from 2.1% in 2024 and 2.9% in 2023.

Risks

• Failure to approve the 2026 Stock Incentive Plan could negatively affect the company's ability to recruit and retain highly qualified employees, which could adversely affect the business.
• Forward-looking statements are subject to inherent risks and uncertainties, and actual results may differ materially from those projected.
• The company's compensation programs, while designed to balance incentives, carry an inherent risk that they could encourage excessive risk-taking, although the company believes this is not reasonably likely.
• The business is subject to various legal and regulatory requirements, including distributor compliance, direct selling practices, FTC and FDA mandates, and FCPA compliance, which could lead to penalties if not adhered to.
• Data protection and privacy practices represent a significant risk, with oversight provided by the Cybersecurity Committee, but breaches could still occur.

Future Outlook

The company intends to continue holding annual shareholder advisory votes on executive compensation, with the next frequency vote scheduled for the 2029 Annual Meeting. The proposed 2026 Stock Incentive Plan is critical for the company's long-term strategy to attract and retain key personnel, ensuring continued growth and financial success. The company does not currently plan to grant stock options, stock appreciation rights, or similar appreciation-based awards as incentive compensation.

Management Comments

• The Board's leadership structure is appropriate, providing unified and consistent leadership, effective independent oversight, and expertise in managing complex consumer product and direct selling operations.
• The compensation program is designed to reward executives under a pay-for-performance philosophy, align with shareholder value creation, and maintain competitive compensation to attract and retain the executive team.
• The company does not believe its compensation programs and incentives are reasonably likely to encourage excessive risk-taking that could harm the Company.

Industry Context

StockSavvy.ai notes that the company operates in the consumer product and direct selling business, a sector characterized by intense competition and evolving consumer preferences. The board's emphasis on digital experience and e-commerce expertise reflects a broader industry trend towards digital transformation and direct-to-consumer models. The appointment of Kenneth Romanzi, with extensive CPG experience, suggests a strategic focus on brand management and driving growth in a competitive market. The company's positive financial performance in 2025, including increased net sales and Adjusted EBITDA, indicates resilience and effective strategy execution within this dynamic industry.

Comparison to Industry Standards

• The company utilizes a peer group of 15 publicly traded U.S. based specialty retail and personal product companies for market benchmarking executive compensation, which included BellRing Brands, Lifetime Brands, Medifast, Sun Opta, Calavo Growers, LifeVantage, Nu Skin, Tupperware Brands, e.l.f. Beauty, Lifeway Foods, PetMed Express, USANA Health Sciences, Land's End, Limoneira, and SpartanNash Company in 2023.
• The 2024 peer group was updated to remove two peers and add three new ones: Honest Company, Oil-Dri of America, and Vital Farms, ensuring the benchmark remains relevant.
• The CEO's base salary (for both Mr. Romanzi and former CEO Mr. Moorehead) was set below the median salary level of the peer group, indicating a potentially cost-effective approach to executive compensation.
• Relative Total Shareholder Return (TSR) awards for Performance-Contingent Restricted Stock Units (PRSUs) are measured against a peer group of consumer-facing R2000 constituents, with targets allowing participants to earn up to 150% of the target value based on percentile achievement (e.g., 55th percentile for 100% target, 85th percentile for 150% maximum), aligning executive incentives with market performance.

Management Changes

Corporate Governance

Legal Proceedings

• To the company's knowledge, there are no pending material legal proceedings in which any directors, nominees, or their associates are adverse parties or have a material interest adverse to the company or its affiliates.
• To the company's knowledge, there have been no events under any bankruptcy act, criminal proceedings, judgments, sanctions, or injunctions material to the evaluation of the ability or integrity of any directors or nominees during the past 10 years.

Related Party Transactions

• The Audit Committee is responsible for reviewing, approving, or ratifying related-party transactions exceeding $120,000 or 1% of the average of the company's total assets at year-end for the last two completed fiscal years.
• Since the beginning of the 2024 fiscal year, there have been no transactions, and there are currently no proposed transactions, in excess of the specified threshold between the company (or its subsidiaries) and a related person with a direct or indirect material interest.
• Of the fees paid to Director Rong Yang, $26,667 were paid to Fosun Pharma.

Stakeholder Impact

• Shareholders will directly impact corporate governance through their votes on director elections, executive compensation, auditor ratification, and the new 2026 Stock Incentive Plan, which could lead to increased equity dilution.
• Employees and key personnel will benefit from the proposed 2026 Stock Incentive Plan, which is crucial for attracting and retaining talent, thereby impacting the company's long-term operational stability and growth.
• Executive officers and directors are subject to stringent corporate governance policies, including stock ownership guidelines and prohibitions on hedging, aligning their interests with long-term company performance.
• The company's strong financial performance in 2025 (increased sales, net income, Adjusted EBITDA, and TSR) positively impacts shareholders by demonstrating value creation and operational efficiency.

Next Steps

• Shareholders will vote on the election of eight directors at the 2026 Annual Meeting on May 6, 2026.
• Shareholders will vote on an advisory, non-binding resolution to approve named executive officer compensation.
• Shareholders will ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• Shareholders will vote to approve the Nature's Sunshine Products, Inc. 2026 Stock Incentive Plan.
• The company will disclose the final voting results in a current report on Form 8-K following the Annual Meeting.
• The next vote on the frequency of the 'say on pay' vote will be held at the 2029 Annual Meeting.
• Shareholders wishing to submit a proposal for the 2027 Annual Meeting to be included in the proxy statement must do so by November 20, 2026.

Key Dates

Recommendation

The company demonstrated strong financial performance in 2025 with notable increases in net sales, net income, and Adjusted EBITDA, alongside a robust Total Shareholder Return. The appointment of a new CEO with extensive CPG experience and a board focused on corporate governance, risk management, and digital transformation positions the company for continued strategic growth. While the potential for dilution from the new stock incentive plan exists, it is a necessary tool for talent retention and long-term value creation. The overall positive financial trajectory and strategic leadership suggest a favorable outlook for investors.

Keywords

Nature's Sunshine Products, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Stock Incentive Plan, Director Election, Financial Performance, Net Sales, Adjusted EBITDA, Shareholder Return, Risk Management, Deloitte & Touche LLP, Consumer Packaged Goods, Direct Selling, Nutritional Health, E-commerce